Active11816536Private limited companyLondon

CEBRENEX LIMITED

Companies HouseCompanies House

From public filings as at 31 Aug 2026; may contain errors or be out of date. Verify at Companies House · Terms

Watch this company

Get an email when Companies House records a change for Cebrenex Limited: status, filings, accounts, officers or owners. Free.

Not live yet: alerts start by 15 December 2026. We store your email and this company number only, for these alerts. If alerts don’t launch, we tell you and delete your address. Privacy

Coming soon · product and service lists

What does Cebrenex Limited sell?

Registered activity: Wholesale of pharmaceutical goods (SIC 46460). We’re building product and service lists for UK companies. Get this one when it’s ready.

One email, only about this. If we don’t launch within 60 days we’ll tell you. Privacy
01

Summary

Generated from filed data · no estimates

CEBRENEX LIMITED is an active private limited company (company number 11816536) incorporated on 11 February 2019, registered in London. Its registered activity is wholesale of pharmaceutical goods (SIC 46460). Latest micro accounts cover the period ending 28 February 2026, showing net assets of £28k, with 1 employee on average. As micro-entity accounts, no profit and loss account is filed, so turnover and profit are not public. Net assets rose 4% on the prior period (£27k).

Peer position · net assets

By net assets it sits in the upper half of 435 comparable companies in London (median £2,000, upper quartile £90k).

02

Ownership and control

0 active · 1 other

No active person with significant control is registered.

  • persons with significant control statement · since 11 February 2019

Persons with significant control hold 25% or more of shares or voting rights. Smaller shareholdings are only listed in confirmation-statement documents. Directors and secretaries: see the officers list at Companies House.

03

Key dates

Incorporated
11 February 20197 yrs ago
Next accounts due
28 November 2027in 399 days
Confirmation statement due
25 February 2027in 123 days

Due dates are expected from Companies House filing rules; confirm on the official register before relying on them.

04

Activity

SIC 46460
Wholesale of pharmaceutical goods
Accounts type
Micro Entity
Size band
MicroCompanies Act thresholds
05

Financials

2 periods on record · latest ending 28 February 2026
Net assets
£28k
+4%vs Feb 2025
Cash at bank
Not reported
Turnover
Not disclosed
Employees
1
No changevs Feb 2025
Net assets
£28k
Average employees
1
Filed accounts by period, newest first
Period endNet assetsCashDebtorsCreditors <1yTurnoverProfitEmployees
28 February 2026£28k——£4,410——1
28 February 2025£27k——£3,893——1
Current ratio7.41Current assets ÷ creditors within one year

Figures as filed in iXBRL accounts at Companies House. "—" means the line was not reported in that filing; micro-entity accounts contain no profit and loss account.

06

Filing and accounts signals

Facts from the register · no rating
  • Net assets above zeroNet assets £28,249 at 28 February 2026
  • Current assets at least 1.5× creditors within one yearCurrent ratio 7.41
  • Incorporated five or more years agoIncorporated 11 February 2019

Neutral facts read from the register and filed accounts, each with its evidence. They are not a rating, a prediction or advice, and may be incomplete or out of date. How each signal is derived.

07

Timeline

Newest first
  1. Next accounts duein 399 days
  2. Confirmation statement duein 123 days
  3. Accounts period endNet assets £28k · micro accounts
  4. Accounts period endNet assets £27k · micro accounts
  5. Incorporated
08

Similar companies in London

Same activity (wholesale of pharmaceutical goods), closest in incorporation date
09

Reminders for CEBRENEX LIMITED

Get an email before each filing deadline — accounts and confirmation statement — so nothing is late.

Source: Companies House register, snapshot 2026-08-31; accounts from the Companies House accounts data product. Open Government Licence v3.0. View on Companies House. Methodology · About · Markdown.